PanCAN has invested $25 million in the study, which will screen blood samples from new-onset diabetes patients for biomarkers associated with pancreatic cancer.
The company will use the funds to accelerate the clinical development and commercialization of its minimal residual disease detection C2-Intelligence Platform.
Flagship will use its RNAscope assay and image analysis to screen advanced gastric and gastroesophageal cancer patients for elevated DKK1 RNA expression.
The team will use NanoView's ExoView platform to characterize PD-L1 and other biomarkers carried by exosomes in plasma samples from patients undergoing therapy.
The combined company is expected to receive $353 million in gross proceeds, which will help advance several of Tango's precision oncology drug candidates.